News & Updates

Long-term bulevirtide use safe, efficacious in chronic HDV
Long-term bulevirtide use safe, efficacious in chronic HDV
29 Sep 2024 byStephen Padilla

Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.

Long-term bulevirtide use safe, efficacious in chronic HDV
29 Sep 2024
Large UK study underpins role of COVID-19 vax in mental illness
Large UK study underpins role of COVID-19 vax in mental illness
27 Sep 2024
Acute kidney injury: An under-recognized complication of seasonal flu
Acute kidney injury: An under-recognized complication of seasonal flu
25 Sep 2024
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024 byJairia Dela Cruz

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024
Surgery, mechanical aspiration do not prevent death in tricuspid valve infective endocarditis
Surgery, mechanical aspiration do not prevent death in tricuspid valve infective endocarditis
24 Sep 2024
What fuels flu, pneumococcal vaccine hesitancy in SG?
What fuels flu, pneumococcal vaccine hesitancy in SG?
23 Sep 2024 byJairia Dela Cruz

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

What fuels flu, pneumococcal vaccine hesitancy in SG?
23 Sep 2024